Preview

Вопросы современной педиатрии

Расширенный поиск

ЭФФЕКТИВНОСТЬ ПРОФИЛАКТИКИ ПНЕВМОКОККОВЫХ ИНФЕКЦИЙ У ИММУНОКОМПРОМЕТИРОВАННЫХ БОЛЬНЫХ

https://doi.org/10.15690/vsp.v11i3.291

Полный текст:

Аннотация

Среди иммунокомпрометированных пациентов заболеваемость и смертность от инфекций и их осложнений значительно превышает аналогичный показатель у иммунокомпетентного населения. Необходима разработка четких показаний к вакцинации иммунокопрометированных больных как с врожденными, так и приобретенными иммунодефицитами. Благодаря более широкому применению иммуносупрессивной терапии, внедрению биологических препаратов с антицитокиновым механизмом действия растет число вторично иммунокомпрометированных больных. В настоящем обзоре проанализирован опыт специфической профилактики пневмококковой инфекции у разных групп иммунодефицитных больных.

Об авторе

Е. В. Галкина-Лазарева
Клиника Alliance Francaise ООО «РУСАВИАМЕД», Москва

Галкина-Лазарева Елизавета Всеволодовна, кандидат медицинских наук, заведующая педиатрическим отделением клиники Alliance Francaise ООО «РУСАВИАМЕД»



Список литературы

1. Эпидемиология и вакцинопрофилактика инфекции, вызываемой Streptococcus pneumoniae. Методические рекомендации МР 3.3.1.0027-11. 2011. С. 2.

2. Козлов Р.С. Пневмококки: прошлое, настоящее и будущее. Смоленск: Смоленская государственная медицинская академия. 2005. 128 с.

3. Баранов А. А., Намазова Л. С., Таточенко В. К. Пнев мококковая инфекция и связанные с ней заболевания — серьезная проблема современного здравоохранения. Педиатрическая фармакология. 2008; 5 (1): 28–33.

4. Таточенко В. К. Пневмококковая инфекция. Бюллетень «Вакцинация». 2009; 2.

5. Учайкин В. Ф., Шамшева О. В. Пневмококковая инфекция. Руководство по клинической вакцинологии Москва. 2006.

6. Конъюгированная пневмококковая вакцина для иммунизации детей. Рекомендации ВОЗ. Педиатрическая фармакология. 2007; 4 (5): 1–3.

7. Pneumococcal conjugate vaccine for childhood immunization. WHO position paper. Weekly Epidemiol. Rec. 2007; 82: 93–104.

8. Мельникова А. А., Королева И. С., Белошицкий Г. В. Актуальные проблемы пневмококковой инфекции. Ремедиум. 2009; 4: 18–20.

9. Quinton L., Happel K., Gamble L. et al. Pulmonary host defense: basic mechanisms and strategies for immunomodulation In: Niederman MS, Eds. Severe Pneumonia: Lung Biology in Health and Science. 2005: 383–411.

10. O'Brien D. P., Briles D. E., Szalai A. J. et al. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect. Immun. 1999; 67: 595–601.

11. Lauw F. N., Branger J., Florquin S. IL 18 improves the early antimicrobial host response to pneumococcal pneumonia. J. Immunol. 2002; 168: 372–378.

12. Koedel U., Angele B., Rupprecht T. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J. Immunol. 2003; 170: 438–444.

13. Haraguchi S., Day N. K., Nelson R. PJr. Interleukin 12 deficiency associated with recurrent infections. Proc. Natl. Acad. Sci. 1998; 95: 13125–13129.

14. Picard C., Puel A., Bustamante J. et al. Primary immunodeficiencies associated with pneumococcal disease. Curr. Opin. Allergy. Clin. Immunol. 2003; 3: 451–459.

15. Kruetzmann S., Rosado M. M., Weber H. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 2003; 197: 939–945.

16. Primary Immunodeficiency Diseases. URL: http://www.info4pi.org/ aboutPI/index.cfm?section=aboutPI&content=syndromes&area=9

17. Снегова Н. Ф., Харит С. М. Основные подходы к иммунизации детей с первичными иммунодефицитами. Иммунодефициты. 2003; 6 (30).

18. Uzel G. The range of defects associated with nuclear factor B essential modulator. Curr. Opin. Allergy Clin. Immunol. 2005; 5: 513–518.

19. Von Bernuth H., Puel A. Casanova J. L. et al. Septicemia without sepsis: inherited disorders of nuclear factor-B-mediated inflammation. Clin. Infect. Dis. 2005; 41: S436–S439.

20. Goldacker S., Draeger R., Warnatz K. Active vaccination in patients with common variable immunodeficiency (CVID). Clin. Immunol. 2007; 124 (3): 294–303.

21. Nima R., Seyed D. S. et al. Serum Bactericidal Antibody Response 1 Year after Meningococcal Polysaccharide Vaccination of Patients with Common Variable. Immunodeficiency Clinical and Vaccine Immunology. 2010; 17 (4): 524–528.

22. Slatter M. A., Bhattacharya A., Cant A. J. et al. Polysaccharide antibody responses are impaired post bone marrow transplantation for severe combined immunodeficiency, but not other primary immu nodeficiencies. Bone Marrow Transplantation. 2003; 32: 225–229.

23. Engelhard D., Cordonnier C., Shaw P. J. et al. On behalf of the Infectious Disease Working Party of the European Bone Marrow Transplantation (IDWP-EBMT). Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br. J. Haematol. 2002; 117: 444–450.

24. Giebink G. S., Warkentin P. I., Ramsay N. K. C. et al. Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine. J. Infect. Dis. 1986; 154: 590–596.

25. Hammarstrom V., Pauksen K., Azinge J. et al. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction. Support Care Cancer. 1993; 1: 195–199.

26. Velardi A., Cucciaioni S., Terenzi A. et al. Acquisition of Ig isotype diversity after bone marrow transplantation in adults. J. Immunol. 1988; 141: 815–820.

27. Avanzini M. A., Carra A. M., Maccario R. et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J. Clin. Immunol. 1995; 15: 137–144.

28. Griffiths H., Lea J., Bunch C. et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin. Exp. Immunol. 1992; 89: 374–377.

29. Wilfert C. M. Invasive Bacterial Infections in Children with HIV Infection. Pediatric AIDS. Baltimore. 2000. Р. 117–124.

30. Graham S. M. HIV and respiratory infections in children. Curr. Opin. Pulm. Med. 2003; 9 (3): 215–220.

31. Whitney C. G., Farley M. M., Hadler J. et al. Increasing prevalence of multidrug-resistant Streptococcus pneumonia in the United States. N. Engl. J. Med. 2000; 343: 1917–1924.

32. Report of a Consultative Meeting of Children with Pneumonia and HIV Infection. World Health Organization. Harare, Zimbabwe. 2003.

33. Gibb D., Castro J. E., Widhopf G. F. 2nd et al. Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency vir us infection. Pediatr. Infect. Dis. J. 1995; 14 (2): 129–135.

34. Madhi S. A., Kuwanda L., Cutland C. et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr. Infect. Dis. J. 2005; 24 (5): 410–416.

35. King, J. C., Vink P. E., Farley J. J. et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than two years with and without human im munodeficiency virus infection. Pediatrics. 1997; 99 (4): 575–580.

36. Penaranda M., Falco V., Payeras A. et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case control study. Clin. Infect. Dis. 2007; 42: 82–87.

37. Eyasu H. T., Debra H., Brendan F. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States 1998–2003. Vaccine. 2008; 26: 5830–5834.

38. Sims R. V., Steinmann W. C., McConville J. H. et al. Ann Intern Med. 1988; 108: 653–657.

39. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices. MMWR. 1997; 46 (RR-8): 1.

40. Adam U., Halit Y., Ahmet A. The efficacy and immunogenecity of Pneumo-23 and ACT-HIB in patients undergoing splenectomy. Turkish Journal of Trauma & Emergency Surgery Ulus Travma Acil Cerrahi Derg. 2006; 12 (4): 277–281.

41. Shapiro E. D., Berg A. T., Austrian R. et at. N. Engl. J. Med. 1991; 325: 1453–1460. Pneumococcal Disease. MMWR. 1997; 46: RR-8.

42. Маринич И. Г., Тимошенко О. Ф., Игнатьева Г. С. и соавт. Леталь- ность от гриппа и других острых респираторных заболеваний и острой пневмонии в Санкт-Петербурге. Вакцинация. 1999; 5: 4–5.

43. Sims R. V., Steinmann W. C., McConville J. H. et al. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 1988; 108: 653–657.

44. Doran M. F., Crowson C. S., Pond G. R. et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002; 46: 2287–2293.

45. Wolfe F., Mitchell D. M., Sibley J. T. et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37: 481–494.

46. Bosch X., Guilabert A., Pallares L. et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 2006; 15: 584–589.

47. Falagas M. E., Manta K. G., Betsi G. I. et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin. Rheumatol. 2007; 26: 663–670.

48. Bijl1 M., Kallenberg C. G. M., van Assen S. Vaccination of immunocompromised patients with autoimmune-inflammatory diseases. The Netherlands Journal of Medicine. 2011; 69 (1).

49. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. October 2003; 9 (10): 1245–50.

50. Petri M. Infection in systemic lupus erythematosus. Rheum Dis. Clin. North. Am. 1996; 24: 423–456.

51. Mounzer K. C., Dinubile M. Prophylactic use of antibiotics and vaccines in patients with rheumatologic disorders. Rheum. Dis. Clin. North. Am. 1997; 23: 259–275.

52. Bouza E., Moya J. G., Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis. Clin. North. Am. 2001; 15: 335–361.

53. Dillon A. M., Stein H. B., English R. A. Splenic atrophy in Systemic Lupus Erythematosus. Ann. Intern. Med. 1982; 96: 40–43.

54. Wachtel T. J., Fredericks R. Prediction of ventricular function from plain chest roentgenogram. R. I. Med. J. 1986; 69: 589–591.

55. Malleson P., Petty R. E., Nadel H. et al. Functional asplenia in childhood onset Systemic Lupus Erythematosus. J. Rheumatol. 1988; 15: 1648–1652.

56. Kamdar N., Zanzi I., Kroop S. et al. Reversible functional asplenia in Systemic Lupus Erythematosus. Clin Nucl Med. 1991; 16: 760–762.

57. Klippel J. H., Karsh J., Stahl N. et al. A controlled study of pneumococcal polysaccharide vaccine in Systemic Lupus Erythematosus. Arthritis Rheum. 1979; 22: 1321–1325.

58. Jarrett M. P., Schiffman G., Barland P., Grayzel A. I. Impaired response to pneumococcal vaccine in SLE. Arthritis Rheum. 1980; 23: 1287–1293.

59. Lipnick R. N., Karsh J., Stahl N. I. et al. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J. Rheumatol. 1985; 12: 1118–21.

60. Battafarano D. F., Battafarano N. J., Larsen L. et al. Antigenspecific antibody responses in lupus patients following immunization. Arthritis. Rheum. 1998; 41: 1828–1834.

61. Tarijan P., Sipka S., Marodi L. et al. No short-term immunological effects of Pneumococcus vaccination in patients with Systemic Lupus Erythematosus. Scand J. Rheumatol. 2002; 31: 211–215.

62. Elkayam O., Paran D., Caspi D. et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis and Systemic Lupus Erythematosus. Clin. Infect. Dis. 2002; 34: 147–153.

63. Elkayam O., Paran D., Burke M. et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity. 2005; 38 (7): 493–496.

64. Fabrizio C., Soheila R. Guido V. Vaccination and Rheumatic Diseases: Is There Still a Dilemma? Current Rheumatology Reviews. 2007; 3: 79–91.

65. Doran M. F., Crowson C. S., Pond G. R. et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2294–2300.

66. Kroesen S., Widmer1 A. F., Tyndall A. et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-a therapy. Rheumatology. 2003; 42: 617–621.

67. Baghai M., Osmon D. R., Wolk D. M. et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin. Proc. 2001; 76: 653–656.

68. Elkayam O., Caspi D., Reitblatt T. et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis. Rheum. 2004; 33: 283–288.

69. Visvanathan S., Weiss R., Keenan G. et al. Response to the pneumococcal vaccine in patients with Early Rheumatoid Arthritis. Ann. Rheum. Dis. 2005; 64 (Suppl. III): 422.

70. Kapetanovic M. C., Saxne T., Sjoholm A. et al. Influenza of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with reumatoid arthritis. Rheumatology. 2006; 45: 106–111.


Для цитирования:


Галкина-Лазарева Е.В. ЭФФЕКТИВНОСТЬ ПРОФИЛАКТИКИ ПНЕВМОКОККОВЫХ ИНФЕКЦИЙ У ИММУНОКОМПРОМЕТИРОВАННЫХ БОЛЬНЫХ. Вопросы современной педиатрии. 2012;11(3):12-17. https://doi.org/10.15690/vsp.v11i3.291

For citation:


Galkina-Lazareva E.V. EFFICACY OF PNEUMOCOCCAL INFECTIONS PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS. Current pediatrics. 2012;11(3):12-17. (In Russ.) https://doi.org/10.15690/vsp.v11i3.291

Просмотров: 267


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)